• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口腔和喉鳞状细胞癌肿瘤突变负担的差异。

Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.

机构信息

Cancer Center, The First Hospital of Jilin University, 71 Xinmin Ave, Changchun, China.

Department of Gastrointestinal Colorectal and Anal Surgery, The First Hospital of Jilin University, 71 Xinmin Ave, Changchun, China.

出版信息

Oral Oncol. 2021 Mar;114:105142. doi: 10.1016/j.oraloncology.2020.105142. Epub 2021 Jan 16.

DOI:10.1016/j.oraloncology.2020.105142
PMID:33465682
Abstract

OBJECTIVES

This study aimed to evaluate the difference in tumor mutation burden (TMB) between oral cavity squamous cell carcinoma (OCSCC) and larynx squamous cell carcinoma (LSCC).

MATERIALS AND METHODS

Patients with OCSCC or LSCC were identified from datasets within The Cancer Genome Atlas. Somatic mutations and clinical information were included in the analysis. A Poisson regression model was used to evaluate the association of TMB with the primary cancer sites.

RESULTS

We identified 5 datasets that included 396 OCSCC patients and 143 LSCC patients. Patients with LSCC had a significantly higher TMB than patients with OCSCC (crude risk ratio: 0.60, 95% confidence interval: 0.51-0.70, P < 0.001; adjusted risk ratio: 0.57, 95% confidence interval: 0.49-0.66, P < 0.001).Subgroup analyses suggested that this difference was independent of dataset, age, sex, race, alcohol drinking, smoking status, pathological risk, tumor grade, and tumor stage. Sensitivity analyses confirmed the robustness of this finding.

CONCLUSION

To the best of our knowledge, this is the first study to identify a significant difference in TMB between OCSCC and LSCC. Though preliminary, these findings might have implications for guiding the development of trials for examining the response of head and neck carcinomas to immune checkpoint inhibitor treatments.

摘要

目的

本研究旨在评估口腔鳞状细胞癌(OCSCC)和喉鳞状细胞癌(LSCC)之间肿瘤突变负担(TMB)的差异。

材料与方法

从癌症基因组图谱(TCGA)的数据库中确定 OCSCC 或 LSCC 患者。分析中纳入了体细胞突变和临床信息。采用泊松回归模型评估 TMB 与原发性癌症部位的相关性。

结果

我们确定了 5 个数据集,共纳入 396 例 OCSCC 患者和 143 例 LSCC 患者。LSCC 患者的 TMB 明显高于 OCSCC 患者(粗风险比:0.60,95%置信区间:0.51-0.70,P<0.001;调整风险比:0.57,95%置信区间:0.49-0.66,P<0.001)。亚组分析表明,这种差异独立于数据集、年龄、性别、种族、饮酒、吸烟状况、病理风险、肿瘤分级和肿瘤分期。敏感性分析证实了这一发现的稳健性。

结论

据我们所知,这是第一项确定 OCSCC 和 LSCC 之间 TMB 存在显著差异的研究。尽管初步研究,但这些发现可能对指导头颈部癌对免疫检查点抑制剂治疗反应的试验开发具有指导意义。

相似文献

1
Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.口腔和喉鳞状细胞癌肿瘤突变负担的差异。
Oral Oncol. 2021 Mar;114:105142. doi: 10.1016/j.oraloncology.2020.105142. Epub 2021 Jan 16.
2
Gene Expression Subtype Predicts Nodal Metastasis and Survival in Human Papillomavirus-Negative Head and Neck Cancer.基因表达亚型可预测人乳头瘤病毒阴性头颈癌的淋巴结转移及生存情况。
Laryngoscope. 2019 Jan;129(1):154-161. doi: 10.1002/lary.27340. Epub 2018 Sep 24.
3
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery.肿瘤突变负担对接受术前治疗的口腔鳞状细胞癌患者的预后价值。
ESMO Open. 2021 Aug;6(4):100178. doi: 10.1016/j.esmoop.2021.100178. Epub 2021 Jun 9.
4
Distinctive clinical and microscopic features of squamous cell carcinoma of oral cavity and lip.口腔和唇部鳞状细胞癌的独特临床及微观特征。
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar;109(3):e74-9. doi: 10.1016/j.tripleo.2009.10.034.
5
TERT promoter mutation positive oral cavity carcinomas, a clinically and genetically distinct subgroup of head and neck squamous cell carcinomas.TERT 启动子突变阳性口腔癌,头颈鳞状细胞癌中具有临床和遗传特征的亚群。
Head Neck. 2023 Dec;45(12):3107-3118. doi: 10.1002/hed.27540. Epub 2023 Oct 10.
6
Characterization of dendritic cells in lip and oral cavity squamous cell carcinoma.唇与口腔鳞状细胞癌中树突状细胞的特征分析
J Oral Pathol Med. 2016 Jul;45(6):418-24. doi: 10.1111/jop.12380. Epub 2015 Oct 30.
7
Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma.超敏检测口腔鳞状细胞癌患者唾液中的肿瘤特异性突变。
Cancer. 2021 May 15;127(10):1576-1589. doi: 10.1002/cncr.33393. Epub 2020 Dec 21.
8
A comparative study of microvessel density in squamous cell carcinoma of the oral cavity and lip.口腔和唇部鳞状细胞癌中微血管密度的比较研究。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar;113(3):391-8. doi: 10.1016/j.tripleo.2011.08.010.
9
Clinicopathological and immunohistochemical evaluation of oral and oropharyngeal squamous cell carcinoma in Chilean population.智利人群口腔和口咽鳞状细胞癌的临床病理及免疫组化评估
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5968-77. eCollection 2014.
10
Survival outcomes of First Nations patients with oral cavity squamous cell carcinoma (Poliquin 2014).第一民族口腔鳞状细胞癌患者的生存结果(波利昆,2014年)。
J Otolaryngol Head Neck Surg. 2015 Feb 3;44(1):4. doi: 10.1186/s40463-015-0056-8.

引用本文的文献

1
Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors.对舌鳞状细胞癌免疫类型进行分层以改善预后及对免疫检查点抑制剂的反应。
Cancer Immunol Immunother. 2025 Mar 1;74(4):130. doi: 10.1007/s00262-025-03982-9.
2
Construction of a novel tumor mutation burden-related mRNA signature for prognosis prediction in laryngeal squamous cell carcinoma.构建一种新型与肿瘤突变负荷相关的 mRNA 标志物用于预测喉鳞状细胞癌的预后。
Medicine (Baltimore). 2024 Nov 1;103(44):e40431. doi: 10.1097/MD.0000000000040431.
3
Precise Identification of Recurrent Somatic Mutations in Oral Cancer Through Whole-Exome Sequencing Using Multiple Mutation Calling Pipelines.
通过使用多种突变检测流程的全外显子组测序精确鉴定口腔癌中的复发性体细胞突变
Front Oncol. 2021 Nov 29;11:741626. doi: 10.3389/fonc.2021.741626. eCollection 2021.
4
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中肿瘤突变负荷、程序性死亡受体配体1、患者特征与免疫检查点抑制剂反应之间的关系
Cancers (Basel). 2021 Nov 16;13(22):5733. doi: 10.3390/cancers13225733.